OBJECTIVE: Apolipoprotein(B) [apo(B)] reflects the total mass of atherogenic particles (VLDL, IDL, and LDL), and its increase is associated with cardiovascular disease independently of LDL cholesterol (LDLc) levels. Apo(B) determination has been recently standardized, but attention to regional reference limits is advisable. Our aim was to analyze the frequency of dyslipidemic phenotypes, including those dependent on increased apo(B) in normocholesterolemic type 2 diabetic patients. RESEARCH DESIGN AND METHODS: A total of 100 consecutively seen type 2 diabetic patients (63 men, 37 women; aged 59 +/- 11 years) were included, after excluding those on lipid-lowering therapy. Apo(B) cutoff (1.1 g/l) was obtained from a group of normolipidemic (47 men, 21 women) control subjects, and LDLc, triglycerides, and HDL cholesterol (HDLc) cutoff points were those from the National Cholesterol Education Program guidelines. LDLc levels were obtained by ultracentrifugation if triglyceride levels were > 3.45 mmol/l; otherwise, they were calculated (Friedwald). Apo(B) levels were measured by immunoturbidimetry. RESULTS: Normocholesterolemia (LDLc < 4.13 mmol/l) appeared in 75 of the 100 patients, of whom 55 were normo- and 20 hypertriglyceridemic. Hyperapolipoprotein(B) [hyperapo(B)] was the most frequent lipid disorder, present in 34 (45%) of the normocholesterolemic patients (22 normo- and 12 hypertriglyceridemic). Low HDLc levels were more prevalent (53%) in patients with hyperapo(B) than in the rest (24%). CONCLUSIONS: Hyperapo(B) was found in almost half of the normocholesterolemic type 2 diabetic patients and was frequently associated with low HDLc levels and hypertriglyceridemia. Thus, given its independent association with cardiovascular disease and that it identifies high-risk phenotypes in normocholesterolemic diabetic patients apo(B) should be used to evaluate the lipidic pattern of these patients.
OBJECTIVE:Apolipoprotein(B) [apo(B)] reflects the total mass of atherogenic particles (VLDL, IDL, and LDL), and its increase is associated with cardiovascular disease independently of LDL cholesterol (LDLc) levels. Apo(B) determination has been recently standardized, but attention to regional reference limits is advisable. Our aim was to analyze the frequency of dyslipidemic phenotypes, including those dependent on increased apo(B) in normocholesterolemic type 2 diabeticpatients. RESEARCH DESIGN AND METHODS: A total of 100 consecutively seen type 2 diabeticpatients (63 men, 37 women; aged 59 +/- 11 years) were included, after excluding those on lipid-lowering therapy. Apo(B) cutoff (1.1 g/l) was obtained from a group of normolipidemic (47 men, 21 women) control subjects, and LDLc, triglycerides, and HDL cholesterol (HDLc) cutoff points were those from the National Cholesterol Education Program guidelines. LDLc levels were obtained by ultracentrifugation if triglyceride levels were > 3.45 mmol/l; otherwise, they were calculated (Friedwald). Apo(B) levels were measured by immunoturbidimetry. RESULTS: Normocholesterolemia (LDLc < 4.13 mmol/l) appeared in 75 of the 100 patients, of whom 55 were normo- and 20 hypertriglyceridemic. Hyperapolipoprotein(B) [hyperapo(B)] was the most frequent lipid disorder, present in 34 (45%) of the normocholesterolemic patients (22 normo- and 12 hypertriglyceridemic). Low HDLc levels were more prevalent (53%) in patients with hyperapo(B) than in the rest (24%). CONCLUSIONS:Hyperapo(B) was found in almost half of the normocholesterolemic type 2 diabeticpatients and was frequently associated with low HDLc levels and hypertriglyceridemia. Thus, given its independent association with cardiovascular disease and that it identifies high-risk phenotypes in normocholesterolemic diabeticpatients apo(B) should be used to evaluate the lipidic pattern of these patients.
Authors: Y Jamshidi; S B Gooljar; H Snieder; X Wang; D Ge; R Swaminathan; T D Spector; S D O'Dell Journal: Atherosclerosis Date: 2007-01-09 Impact factor: 5.162
Authors: Carl A Hubel; Robert W Powers; Sunna Snaedal; Hilary S Gammill; Roberta B Ness; James M Roberts; Reynir Arngrímsson Journal: Hypertension Date: 2008-04-14 Impact factor: 10.190
Authors: Ivan Tkác; Ján Salagovic; Miriam Kozárová; Hana Rosolová; Angela Molcányiová; Dana Mosorjáková; Martina Chleborádová; Ivan Kalina Journal: Wien Klin Wochenschr Date: 2003-01-31 Impact factor: 1.704
Authors: John J Albers; Santica M Marcovina; Giuseppina Imperatore; Beverly M Snively; Jeanette Stafford; Wilfred Y Fujimoto; Elizabeth J Mayer-Davis; Diana B Petitti; Catherine Pihoker; Larry Dolan; Dana M Dabelea Journal: J Clin Endocrinol Metab Date: 2007-12-18 Impact factor: 5.958
Authors: Sangheun Lee; In Tae Kim; Hyung Bok Park; Yu Kyung Hyun; Yoon Ji Kim; Sun Ok Song; Hyeongjin Kim Journal: J Korean Med Sci Date: 2011-10-01 Impact factor: 2.153
Authors: Kenneth O Inaku; Obasola O Ogunkeye; Fayeofori M Abbiyesuku; Evelyn K Chuhwak; Christian O Isichei; Lucius C Imoh; Noel O Amadu; Alexander O Abu Journal: BMC Clin Pathol Date: 2017-12-06